Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Mar
20
2019
An Artful Deal? Critics Question Administration’s Prescription Drug Negotiation Tools for Medicare Advantage
Nov
28
2022
Key Takeaways from the HLTH 2022 Conference
May
9
2017
Are Secret Sales Prior Art Under The AIA?
Jul
30
2018
Health Care Policy Newsletter - Week of July 23-27, 2018
May
2
2022
Attorney General Garland Reconfirms the DOJ’s Hands-Off Approach Toward Federal Marijuana Prosecution
May
22
2019
340B Rate Cuts: DC Court Enjoins and Remands CMS’ 2018 and 2019 Reductions for Hospital Outpatients
Dec
29
2022
Doctor-Patient Relationships and Medical Marijuana: Where Are We Now?
Oct
6
2015
Beware Reexamination Amendments
May
21
2018
Health Care Policy Newsletter
Oct
26
2021
FDA Calls for Repeating Clinical and Bioanalytical Studies
Nov
22
2021
CMS Changes Course by Repealing the Medicare Coverage of Innovative Technology and Definition of Reasonable and Necessary Rule Due to Insufficient Beneficiary Protections
Jan
24
2017
Federal Circuit Finds Infringement Under Akamai Of Two-Step Method Of Treatment
May
29
2018
Health Care Policy Newsletter - Week of May 28, 2019
Jul
31
2018
The Battle Over Drug Pricing: First Shot Targets Pharmacy Benefit Managers
Aug
28
2018
Public Policy August Recess Health Care Newsletter
May
2
2018
Direct Provider Contract Alternative Payment Model - CMS/CMMI Issues Request for Information
Jun
12
2018
Florida’s New Law Changes Physician Responsibilities for Opioid Dispensing
May
30
2017
Recent Guidance from Federal Circuit on Doctrine of Equivalents in Cases Involving Chemical Compositions
May
2
2020
Re-Imagining the Shopping Center Post-COVID: Zoning Changes Needed to Accommodate Store Features No Longer Deemed Convenience Amenities Sills Cummis & Gross P.C.
Mar
4
2020
Federal Preemption in the Wake of Albrecht: The U.S. Supreme Court Unexpectedly Levels the Playing Field Sills Cummis & Gross P.C.
Feb
25
2021
New Jersey Cannabis Legalization Imposes New Burdens on Employers Sills Cummis & Gross P.C.
Oct
10
2011
Six Important Strategies To Reduce The Royalty Burden For A Pharmaceutical Product Sills Cummis & Gross P.C.
Feb
19
2015
Life Sciences: Protecting the Crown Jewels Sills Cummis & Gross P.C.
Oct
11
2011
Solar Energy Is Viable For Office Properties Sills Cummis & Gross P.C.
Jul
3
2013
Buyer Beware: Important “Supply” Issues For Life Science Companies Sills Cummis & Gross P.C.
Sep
9
2016
Perdue v. Wyeth Pharmaceuticals, Inc.: A Triple Knockout on Pre-Emption and Innovator Liability Grounds Sills Cummis & Gross P.C.
Apr
5
2023
D’Addario v. Johnson & Johnson – New Jersey Federal Court Addresses Express Pre-Emption In Class III Medical Device Case Sills Cummis & Gross P.C.
Jul
9
2011
The NJ Solar Energy Industry: Boom, Correction And The Future - Part I Sills Cummis & Gross P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins